Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 12/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.32 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.31 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.31 |
| ▸ | XIAP | P98170 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16064068 | 0.96 | CTSC (0.53) | CTSCCTSKPREPDPP4TLR7 | |
| SCHEMBL16064472 | 0.92 | CTSC (0.54) | CTSCCTSKPREP | |
| SCHEMBL17485398 | 0.89 | CTSC (0.61) | CTSCCTSK | |
| SCHEMBL16064451 | 0.89 | CTSC (0.51) | CTSCCTSKPREPDPP4TLR7 | |
| SCHEMBL16064233 | 0.89 | CTSC (0.40) | CTSCCTSKPREPDPP4TLR7 | |
| SCHEMBL16064438 | 0.87 | CTSC (0.52) | CTSCCTSKPREPDPP4 | |
| SCHEMBL16064452 | 0.85 | CTSC (0.67) | CTSCCTSK | |
| SCHEMBL17483595 | 0.85 | CTSC (0.44) | CTSCCTSKPREPDPP4TLR7 | |
| SCHEMBL21076251 | 0.83 | PREP (0.37) | CTSCCTSKPREPDPP4HTRA1 | |
| SCHEMBL20384104 | 0.83 | CTSC (0.42) | CTSCCTSKPREPDPP4HTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3174879-B1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-9440960-B2 | Substituted oxetanes and their use as inhibitors of cathepsin C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-09-13 | — | — | US | disclosed |
| US-20160031861-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-04 | — | — | US | disclosed |
| WO-2016016242-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031861-A1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | CTSE, CTSC, CTSZ | CTSC 2/4885CTSK 10/4885PREP 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.